Galapagos NV (GLPG.AS)
EUR 25.7
(0.78%)
EUR 25.7
(0.78%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -157.2 Million EUR | 67.67% |
| 2022 | -486.21 Million EUR | 77.96% |
| 2021 | -2.2 Billion EUR | -4.78% |
| 2020 | -2.1 Billion EUR | -14.68% |
| 2019 | -1.83 Billion EUR | -42.26% |
| 2018 | -1.29 Billion EUR | -12.13% |
| 2017 | -1.15 Billion EUR | -18.29% |
| 2016 | -973.17 Million EUR | -186.06% |
| 2015 | -340.19 Million EUR | -81.4% |
| 2014 | -187.54 Million EUR | -32.93% |
| 2013 | -141.08 Million EUR | -49.71% |
| 2012 | -94.24 Million EUR | -197.49% |
| 2011 | -31.67 Million EUR | 19.09% |
| 2010 | -39.15 Million EUR | 14.71% |
| 2009 | -45.9 Million EUR | -79.23% |
| 2008 | -25.61 Million EUR | 42.99% |
| 2007 | -44.92 Million EUR | -2.69% |
| 2006 | -43.75 Million EUR | -85.26% |
| 2005 | -23.61 Million EUR | -129.87% |
| 2004 | -10.27 Million EUR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -65.39 Million EUR | 58.4% |
| 2024 Q3 | -51.29 Million EUR | -6.28% |
| 2024 Q2 | -41.45 Million EUR | 36.61% |
| 2023 Q3 | -145.22 Million EUR | -75.8% |
| 2023 Q2 | -82.6 Million EUR | 23.61% |
| 2023 Q1 | -108.13 Million EUR | 77.76% |
| 2023 FY | -157.2 Million EUR | 67.67% |
| 2023 Q4 | -157.2 Million EUR | -8.25% |
| 2022 FY | -486.21 Million EUR | 77.96% |
| 2022 Q1 | -1.22 Billion EUR | 44.3% |
| 2022 Q2 | -948.74 Million EUR | 22.8% |
| 2022 Q4 | -486.21 Million EUR | 25.52% |
| 2022 Q3 | -652.83 Million EUR | 31.19% |
| 2021 Q1 | -2.52 Billion EUR | -19.92% |
| 2021 Q2 | -2.61 Billion EUR | -3.54% |
| 2021 Q4 | -2.2 Billion EUR | 21.42% |
| 2021 Q3 | -2.8 Billion EUR | -7.39% |
| 2021 FY | -2.2 Billion EUR | -4.78% |
| 2020 Q2 | -2.35 Billion EUR | 13.3% |
| 2020 Q3 | -2.05 Billion EUR | 12.65% |
| 2020 Q4 | -2.1 Billion EUR | -2.28% |
| 2020 FY | -2.1 Billion EUR | -14.68% |
| 2020 Q1 | -2.71 Billion EUR | -48.05% |
| 2019 Q4 | -1.83 Billion EUR | 67.06% |
| 2019 FY | -1.83 Billion EUR | -42.26% |
| 2019 Q1 | -1.19 Billion EUR | 7.2% |
| 2019 Q3 | -5.57 Billion EUR | -396.73% |
| 2019 Q2 | -1.12 Billion EUR | 6.31% |
| 2018 Q1 | -1.1 Billion EUR | 3.74% |
| 2018 Q3 | -1.34 Billion EUR | -25.96% |
| 2018 FY | -1.29 Billion EUR | -12.13% |
| 2018 Q4 | -1.29 Billion EUR | 3.93% |
| 2018 Q2 | -1.06 Billion EUR | 3.74% |
| 2017 FY | -1.15 Billion EUR | -18.29% |
| 2017 Q4 | -1.15 Billion EUR | 5.55% |
| 2017 Q3 | -1.21 Billion EUR | 3.42% |
| 2017 Q2 | -1.26 Billion EUR | -32.38% |
| 2017 Q1 | -953.33 Million EUR | 2.04% |
| 2016 Q4 | -973.17 Million EUR | -4.56% |
| 2016 FY | -973.17 Million EUR | -186.06% |
| 2016 Q1 | -978.23 Million EUR | -187.55% |
| 2016 Q2 | -960.39 Million EUR | 1.82% |
| 2016 Q3 | -930.73 Million EUR | 3.09% |
| 2015 Q1 | 187.71 Million EUR | 200.09% |
| 2015 Q2 | -397.33 Million EUR | -311.67% |
| 2015 FY | -340.19 Million EUR | -81.4% |
| 2015 Q4 | -340.19 Million EUR | 7.16% |
| 2015 Q3 | -366.41 Million EUR | 7.78% |
| 2014 Q4 | -187.54 Million EUR | 0.0% |
| 2014 Q2 | -231.27 Million EUR | -4.81% |
| 2014 Q1 | -220.66 Million EUR | -56.4% |
| 2014 FY | -187.54 Million EUR | -32.93% |
| 2013 FY | -141.08 Million EUR | -49.71% |
| 2013 Q3 | -138 Million EUR | -1.34% |
| 2013 Q2 | -136.18 Million EUR | 0.18% |
| 2013 Q4 | -141.08 Million EUR | -2.23% |
| 2013 Q1 | -136.42 Million EUR | -44.76% |
| 2012 Q3 | -94.64 Million EUR | 22.38% |
| 2012 Q4 | -94.24 Million EUR | 0.43% |
| 2012 FY | -94.24 Million EUR | -197.49% |
| 2012 Q2 | -121.93 Million EUR | 0.0% |
| 2011 Q2 | -48.68 Million EUR | 0.0% |
| 2011 FY | -31.67 Million EUR | 19.09% |
| 2011 Q4 | -31.67 Million EUR | 0.0% |
| 2010 Q2 | -25.89 Million EUR | 0.0% |
| 2010 FY | -39.15 Million EUR | 14.71% |
| 2010 Q4 | -39.15 Million EUR | 0.0% |
| 2009 Q2 | -16.99 Million EUR | 0.0% |
| 2009 FY | -45.9 Million EUR | -79.23% |
| 2009 Q4 | -45.9 Million EUR | 0.0% |
| 2008 FY | -25.61 Million EUR | 42.99% |
| 2008 Q4 | -25.61 Million EUR | 0.0% |
| 2007 FY | -44.92 Million EUR | -2.69% |
| 2006 FY | -43.75 Million EUR | -85.26% |
| 2005 FY | -23.61 Million EUR | -129.87% |
| 2004 FY | -10.27 Million EUR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| ABIONYX Pharma SA | -714 Thousand EUR | -21917.787% |
| ABIVAX Société Anonyme | -196.47 Million EUR | 19.987% |
| Adocia SA | 127 Thousand EUR | 123885.039% |
| Aelis Farma SA | -16.19 Million EUR | -870.893% |
| Biophytis S.A. | 2.7 Million EUR | 5916.019% |
| Advicenne S.A. | 12.17 Million EUR | 1391.228% |
| genOway Société anonyme | 2.97 Million EUR | 5387.879% |
| IntegraGen SA | -709.74 Thousand EUR | -22049.661% |
| Medesis Pharma S.A. | 1.15 Million EUR | 13673.273% |
| Neovacs S.A. | -237.08 Thousand EUR | -66207.727% |
| NFL Biosciences SA | -2.27 Million EUR | -6807.556% |
| Plant Advanced Technologies SA | 4.35 Million EUR | 3708.554% |
| Quantum Genomics Société Anonyme | -830.54 Thousand EUR | -18828.105% |
| Sensorion SA | 1.37 Million EUR | 11506.508% |
| Theranexus Société Anonyme | 2.44 Million EUR | 6531.957% |
| TME Pharma N.V. | -1.07 Million EUR | -14469.694% |
| Valbiotis SA | -18.13 Million EUR | -766.68% |
| TheraVet SA | 12.78 Thousand EUR | 1229720.649% |
| Valerio Therapeutics Société anonyme | 2.18 Million EUR | 7311.33% |
| argenx SE | -1.83 Billion EUR | 91.441% |
| BioSenic S.A. | 28.04 Million EUR | 660.573% |
| Celyad Oncology SA | -6.1 Million EUR | -2476.319% |
| DBV Technologies S.A. | -114.95 Million USD | -36.754% |
| Genfit S.A. | -7.61 Million EUR | -1965.524% |
| GeNeuro SA | 5.91 Million EUR | 2759.837% |
| Hyloris Pharmaceuticals SA | -25.11 Million EUR | -526.023% |
| Innate Pharma S.A. | -30.71 Million EUR | -411.875% |
| Inventiva S.A. | 10.48 Million EUR | 1598.78% |
| MaaT Pharma SA | -10.2 Million EUR | -1440.49% |
| MedinCell S.A. | 39.5 Million EUR | 497.982% |
| Nanobiotix S.A. | -24.71 Million EUR | -536.002% |
| Onward Medical N.V. | -12.89 Million EUR | -1119.226% |
| Oryzon Genomics S.A. | 1.43 Million EUR | 11090.929% |
| OSE Immunotherapeutics SA | 27.12 Million EUR | 679.48% |
| Oxurion NV | 10.71 Million EUR | 1567.852% |
| Pharming Group N.V. | 99.4 Million EUR | 258.153% |
| Poxel S.A. | 44.55 Million EUR | 452.806% |
| GenSight Biologics S.A. | 16.29 Million EUR | 1064.815% |
| Transgene SA | -14.4 Million EUR | -991.033% |
| Financière de Tubize SA | 78.62 Million EUR | 299.945% |
| UCB SA | 2.17 Billion EUR | 107.221% |
| Valneva SE | 82.73 Million EUR | 290.01% |
| Vivoryon Therapeutics N.V. | -18.52 Million EUR | -748.667% |